EWA
PTCT icon

Evolution Wealth Advisors’s PTC Therapeutics PTCT Stock Holding History

Evolution Wealth Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-116
Closed -$4K – 513
2021
Q3 		$4K Sell
116
-175
-60% -$7.19K ﹤0.01% 572
2021
Q2 		$12K Buy
291
+8
+3% +$343 ﹤0.01% 385
2021
Q1 		$13K Hold
283
– – ﹤0.01% 375
2020
Q4 		$17K Hold
283
– – ﹤0.01% 284
2020
Q3 		$13K Hold
283
– – ﹤0.01% 324
2020
Q2 		$14K Hold
283
– – ﹤0.01% 248
2020
Q1 		$13K Buy
+283
New +$14.2K 0.01% 189

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Evolution Wealth Advisors's PTCT Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of PTC Therapeutics (PTCT) in Q4 2021, closing a stake of 116 shares — an estimated $4K sold.

Evolution Wealth Advisors first reported a position in PTCT in Q1 2020 and held it in 7 quarters. The position peaked at $17K in Q4 2020. 178 funds tracked by Wall St. Rank hold PTCT as of Q4 2021.

  • Evolution Wealth Advisors reported no remaining PTC Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Evolution Wealth Advisors sold 116 PTC Therapeutics shares in Q4 2021, an estimated $4K.
  • Evolution Wealth Advisors first reported a position in PTC Therapeutics in Q1 2020 and held it in 7 quarters.
  • Evolution Wealth Advisors's PTC Therapeutics position peaked at $17K in Q4 2020.
  • 178 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.